In this study, we report the results of the treatment of patients with drug-resistant pediatric epilepsies caused by different missense variants in four voltage-dependent potassium channels (Kv7.2, Kv7.3, Kv3.1, and KNa1.1) with drugs selected for their ability to counteract mutation-induced channel dysfunction observed in vitro. This evidence concerns the gene KCNQ3 and epilepsy.